Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.3B
47M shares
52-week range
$42.62 – $71.07
18% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
2.1
EV / FCF (TTM)
18.1
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
www.prestigebrands.comNo one on the platform currently holds PBH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 36,702 | $2.2M |
| Bridgewater Associatesas of 2025-09-30 | 9,657 | $602.6K |
No one on the platform has traded PBH yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.0% | — | — | — | ||
| Rev. Growth % | -4.3% | 2.9% | ||||
| Profit Margin % | 17.5% | 13.3% | 13.6% | |||
| Free Cash Flow Margin % | 22.6% | 21.6% | 20.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -2.3% on the P/E track.
At today's price, your expected annual return is +5.2% on the P/E track.
At today's price, your expected annual return is +10.0% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.3B | +17.9% | $4.58 | $4.57–$4.60 | 10.4× | 5 |
| 2028 | $1.4B | +6.6% | $5.13 | $4.93–$5.25 | 9.3× | 5 |
| 2029 | $1.4B | +2.3% | $5.34 | $4.62–$5.55 | 8.9× | 1 |
| 2030 | $1.4B | +1.5% | $5.69 | $4.92–$5.91 | 8.4× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $0.89 | $0.98 | +9.6% |
| 2026-05-13 | $1.39 | $1.23 | -11.5% |
| 2026-02-05 | $1.16 | $1.14 | -1.7% |
| 2025-11-06 | $0.97 | $1.07 | +10.3% |
| 2025-08-07 | $1.01 | $0.95 | -5.9% |
| 2025-05-08 | $1.30 | $1.32 | +1.5% |
| 2025-02-06 | $1.16 | $1.22 | +5.2% |
| 2024-11-07 | $1.08 |
| $1.09 |
| +0.9% |
| -1.85% |
| $4.2B |
| — |
| ICUIICU Medical, Inc. | $156.24 | -0.87% | $3.9B | — |
| IRONDisc Medicine, Inc. | $67.71 | -1.76% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
https://www.marketbeat.com/earnings/reports/2026-8-6-prestige-consumer-healthcare-inc-stock/ $PBH Prestige Consumer Healthcare Earnings Tr
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-6-premium-brands-holdings-co-pbhto-stock/ $PBH Premium Brands Earnings Transcript
View on StockTwits ↗
$PBH - Prestige Consumer Healthcare Inc - 10K - Updated Risk Factors PBH flags heightened supply-chain and manufacturing concentration risk (including a $10.3M supplier loan write-off), worsening geopolitical and shipping cost pressures, persistent sterile eye care capacity constraints despite a new plant, greater exposure to private label and e-commerce platform dynamics, expanding international and sustainability (EPR) compliance burdens, and new cyber, AI, and data-privacy liabilities. #ConsumerHealthcare #SupplyChainRisk #GeopoliticalPressure #ManufacturingConcentration #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/PBH/10-K/2026-05-14
View on StockTwits ↗
https://marketbeat.com/a/8655289/ $PBH Prestige Consumer Healthcare Q4 Earnings Call Highlights
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-5-13-prestige-consumer-healthcare-inc-stock/ $PBH Prestige Consumer Healthcare Earnings T
View on StockTwits ↗
$PBH Q4 '26 Earnings Results & Recap • Reported GAAP EPS of $1.14 up 12.87% YoY • Reported revenue of $281.62M down -5.03% YoY • Prestige Consumer Healthcare Inc. anticipates fiscal 2027 organic revenue growth of 1.0% to 3.0% and adjusted diluted EPS of $4.42 to $4.51, with free cash flow expected to be $250 million or more.
View on StockTwits ↗
Wall St is expecting 1.39 EPS for $PBH Q4 [Reporting 04/30 BMO] http://www.estimize.com/intro/pbh?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Wall St is expecting 1.39 EPS for $PBH Q4 [Reporting 04/30 BMO] http://www.estimize.com/intro/pbh?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗
$PBH Share Price: $55.13 Contract Selected: Oct 16, 2026 $45 Calls Buy Zone: $7.65 – $9.45 Target Zone: $12.57 – $15.37 Potential Upside: 55% ROI Time to Expiration: 192 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
3/6: Prestige Consumer signs definitive agreement to buy Breathe Right and related OTC assets for $1.045 bn in cash. | View: The sizeable $1.045 billion cash acquisition could be value-creating… $PBH $XLP $PG $CL
View on StockTwits ↗
$PBH Q3 earnings miss & revenue beat — what's the impact? 🤔 EPS fell short of the Zacks Consensus Estimate, while revenues managed to top expectations despite a year-over-year decline due to Clear Eyes supply constraints. 📉 The company's fiscal 2026 sales outlook narrows as consumer headwinds persist, affecting order patterns across various channels. Full breakdown here 👉 https://www.zacks.com/stock/news/2861914/pbhs-q3-earnings-miss-estimates-revenues-surpass-stock-up?cid=sm-stocktwits-2-2861914-body-33278&ADID=SYND_STOCKTWITS_TWEET_2_2861914_BODY_33278
View on StockTwits ↗$PBH Q3 mixed bag — but the market’s cheering anyway 👀 Earnings missed estimates, revenues came in ahead, and the stock is up. That tells you where sentiment is leaning right now — top-line strength is winning the narrative. Is this momentum sustainable or just a relief pop? Full breakdown here 👉 https://www.zacks.com/stock/news/2861914/pbhs-q3-earnings-miss-estimates-revenues-surpass-stock-up?cid=sm-stocktwits-2-2861914-teaser-33258&ADID=SYND_STOCKTWITS_TWEET_2_2861914_TEASER_33258
View on StockTwits ↗
$PBH: Prestige Consumer reports EPS in-line, revs in-line; guides FY26 EPS below consensus, revs below consensus https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260205060632PBH&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
View on StockTwits ↗$PBH Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.98 down -20.33% YoY • Reported revenue of $283.44M down -2.37% YoY
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.